Researchers from Rice and Baylor College of Medicine have secured NIH funding to develop a novel, non-DNA-altering CRISPR ...
H.C. Wainwright reiterated a USD 80.00 target for CRISPR Therapeutics on October 9, 2026. The USD 80.00 target stood 60.39 ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
A.J. Silver has served as Senior Vice President of Finance since January 2025. Since joining the company in 2018, he has held leadership roles across strategic finance, treasury, financial planning ...
Dr. Donald Kohn, a UCLA physician-scientist whose work has helped bring life-saving blood stem cell gene therapies from the ...
Raju has been a trusted partner to me and a wonderful colleague during his time at CRISPR Therapeutics," said Samarth ...
Researchers in Australia have reprogrammed the RNA-cutting enzyme PspCas13b to destroy the fusion transcripts that drive many ...
CRISPR Therapeutics (NASDAQ: CRSP), a gene editing-focused biotech, has made significant clinical and regulatory progress ...
This is an analysis of the latest articles on iPS cells and regenerative medicine from around the world, compiled by Troy ...
Infant neuroblastoma is one of the most clinically paradoxical cancers in medicine. Diagnosed during the first year of life, ...
DISABLED ENTREPRENEUR UK on MSN
Cell and gene therapy AI (CGTAI): How artificial intelligence and gene editing could transform medicine
Discover how Cell and Gene Therapy AI (CGTAI), CRISPR gene editing and advanced cell therapies could transform treatments for ...
For someone receiving Casgevy (exagamglogene autotemcel), gene editing involves much more than an infusion. Blood stem cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results